ChemoSNiP
ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug.
ChemoSNiP analyses a blood sample to identify for single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments with chemicals, drugs and other agents.
ChemoSNiP provides clinicians with a powerful insight into which drugs are most effective at treating cancer. The results provide a personalised analysis that can be used to provide the most effective combination of drugs and treatments available.
Purpose of the test
Purpose of the test
Our genetic code is inherited from our parents. Within our genes are variations that affect how we react to certain drugs and treatments for diseases, including cancer.
ChemoSNiP looks for single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments with chemicals, drugs and other agents.
Specifically, ChemoSNIP studies single nucleotide polymorphisms in a patient’s genes that are involved in breaking down cytostatic (anti-cancer) or targeted drugs that are used to treat cancer therapy. The test provides clinicians with crucial information about the ability of each individual to break down and trigger a treatment in the most effective way.
Useful information
Useful information
ChemoSNiP requires two buccal swabs or 7-10 ml of whole (peripheral) blood, to be sent in an immobilising liquid in a 50ml volume Falcon tube.
Support and training
Support and training
RGCC provides phone and online support on how to conduct the test and interpret the results. We also provide regular training courses for clinicians in order to familiarise them with the tests.